The growth inhibitory effect of FGFR inhibition was accompanied by a marked reduction of p-ERK1/2 levels in MRT tumor samples observed in immunohistological and immmunoblot analyses upon short-term, single dose NVP-BGJ398 treatment (Fig. 6B) These results indicate that pharmacological inhibition of FGFR signaling is able to suppress growth of MRTs in vivo. The gene discussed is MAPK3; the disease is neoplasm.